OTCMKTS:BIOYF BioSyent (BIOYF) Stock Price, News & Analysis $10.31 +0.13 (+1.28%) As of 01:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesBuy This Stock About BioSyent Stock (OTCMKTS:BIOYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioSyent alerts:Sign Up Key Stats Today's Range$10.31▼$10.3150-Day Range$9.76▼$10.8952-Week Range$7.63▼$12.00Volume1,103 shsAverage Volume2,888 shsMarket CapitalizationN/AP/E Ratio50.66Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioSyent Inc. is a specialty biopharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products and medical devices. The company leverages expertise in regulatory affairs, clinical development and manufacturing to deliver a range of branded and generic therapies across multiple therapeutic areas, with particular emphasis on endocrine disorders, supportive care oncology and dermatology. BioSyent operates a manufacturing facility in Canada that supports both its proprietary portfolio and contract development and manufacturing services (CDMO) for small-molecule products. Its end-to-end capabilities—encompassing formulation, fill-finish and quality testing—serve clients in North America and selected international markets. The company's commercial footprint spans Canada and the United States, where it markets specialty pharmaceuticals through its dedicated sales force and distribution partnerships. BioSyent continues to bolster its product pipeline through strategic in-licensing, acquisitions and targeted internal development programs, aiming to address evolving patient needs in niche therapeutic segments. Guided by an experienced leadership team with backgrounds in pharmaceutical development and commercialization, BioSyent is focused on sustainable growth through portfolio expansion and manufacturing capacity enhancement. The company's strategy emphasizes high-value specialty products, positioning BioSyent to respond to emerging healthcare trends and regulatory opportunities.AI Generated. May Contain Errors. Read More Receive BIOYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOYF Stock News HeadlinesBioSyent to Present at Planet MicroCap Las VegasJune 15, 2026 | globenewswire.comBioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)May 19, 2026 | globenewswire.comAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion to AI infrastructure in 2026 alone - more than the entire dot-com buildout combined. When Zuckerberg told investors 'we want to make sure we're not underinvesting,' veteran Wall Street analyst Chris Rowe says that wasn't a growth pitch - it was fear. That money flows downstream through chipmakers, network builders, and small data infrastructure companies most investors have never heard of. Rowe spent 30 years tracking institutional money before it moves, and he says this spending won't stop regardless of market conditions - none of these four can afford to be the one who blinked.July 6 at 1:00 AM | True Market Insiders (Ad)BioSyent Declares Second Quarter 2026 DividendMay 14, 2026 | globenewswire.comBioSyent Releases Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comBioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026May 7, 2026 | globenewswire.comBioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | globenewswire.comBioSyent Announces Grant of Restricted Share UnitsMarch 24, 2026 | globenewswire.comSee More Headlines BIOYF Stock Analysis - Frequently Asked Questions How have BIOYF shares performed this year? BioSyent's stock was trading at $9.52 at the beginning of 2026. Since then, BIOYF stock has increased by 8.3% and is now trading at $10.31. How do I buy shares of BioSyent? Shares of BIOYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/06/2026Next Earnings (Estimated)8/25/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:BIOYF CIKN/A Webwww.biosyent.com Phone(905) 206-0013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio50.66 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:BIOYF) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
